Business
Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
Calgary, Alberta--(Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HM...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional GenomicsCalgary, Alberta--(Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (\"Hemostemix\" or the \"Company\") is pleased to announce it has signed a Global Master Services Agreement with My Next Health (\"MNH\"), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.My Next Health Inc. (\"MNH\") is the world's leading patient-based AI-functional genomic medical analysis company. MNH is improving human health and accelerating the world's transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient assessments) and from its comparison of that database to 60 million patient records, MNH has created the world's first functional genomic AI-based tool that delivers precision medical care, significantly improving an individual's health recommendations and clinical trial outcomes. MNH algorithms significantly impact clinical trial subject selection. Hemostemix will incorporate MNH's functional genomic assays to complete an assay report by individual. Such analyses will enable Hemostemix to recruit subjects into its clinical trials who are best suited to achieve both the safety and efficacy results desired from a randomized double blind placebo controlled clinical trial. \"We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine,\" stated Dr. Richard Heinzl, CEO, MNH. \"MNH's tools and analyses enables Hemostemix to explain when, how and why ACP works. These innovations improve the underpinnings of our therapeutics markets, and significantly de-risks our clinical trials going forward,\" stated Thomas Smeenk, CEO. ABOUT MY NEXT HEALTHMy Next Health Inc. (\"MNH\") is the world's leading patient focused, AI-functional-medicine-based genomic medical analysis company. MNH is improving human health and accelerating the world's transition to precision medicine. From completing more than 10,000 i...